Summary
This Lancet Commission paper argues for a paradigm shift in the understanding and management of coronary artery disease, moving away from ischaemia as the primary therapeutic target towards the identification and treatment of atherosclerotic plaque. Drawing on a large multidisciplinary international authorship, the commission likely synthesises evidence from imaging, interventional, and pharmacological studies to support this reframing. The work has potential implications for clinical practice guidelines, diagnostic pathways, and the prioritisation of lipid-lowering and anti-inflammatory therapies.
UK applicability
The commission's recommendations are broadly applicable to UK clinical practice, particularly within NHS cardiology services and NICE guideline development, given the UK's substantial burden of coronary artery disease and existing investment in cardiac imaging infrastructure.
Key measures
Cardiovascular event rates; atherosclerotic plaque burden; ischaemic burden; diagnostic accuracy metrics; clinical outcome data from reviewed trials
Outcomes reported
The commission examined the evidence base for reframing coronary artery disease management around atherosclerotic plaque (atheroma) rather than ischaemia, likely reporting on diagnostic strategies, treatment outcomes, and implications for clinical guidelines. It is expected to assess how an atheroma-centred approach affects patient outcomes including cardiovascular events and mortality.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.